You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ibi310

Showing 1 - 9 of 9
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

MSI-H Trial in Guangzhou (IBI310, Radical surgery, Sintilimab)

Not yet recruiting
  • MSI-H
  • IBI310
  • +2 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
May 26, 2023

Advanced Biliary Tract Cancer Trial in Changsha (IBI310, sintilimab)

Not yet recruiting
  • Advanced Biliary Tract Cancer
  • Changsha, Hunan, China
    Hunan cancer Hospital
Dec 13, 2022

NPC Trial in Guangzhou (Sintilimab, IBI310)

Active, not recruiting
  • NPC
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 3, 2022

NSCLC (Non-small-cell Lung Cancer) Trial in Changchun (Sintilimab, IBI310)

Recruiting
  • NSCLC (Non-small-cell Lung Cancer)
  • Changchun, Jilin, China
    The First Hospital of Jilin University
Sep 21, 2022

Hepatocellular Carcinoma Trial in Shanghai (IBI310, Sintilimab, Sorafenib)

Recruiting
  • Hepatocellular Carcinoma
  • IBI310
  • +2 more
  • Shanghai, Shanghai, China
    Fudan Universtiy Zhongshan Hospital
Sep 16, 2022

Neuroendocrine Tumor Trial in Beijing (Sintilimab, IBI310, Surufatinib)

Recruiting
  • Neuroendocrine Neoplasm
  • Beijing, Beijing, China
  • +1 more
Dec 7, 2021

Healthy Subjects Trial in Shanghai (Ipilimumab, IBI310)

Recruiting
  • Healthy Subjects
  • Shanghai, China
    Huashan Hospital Affiliated to Fudan University
Jun 21, 2021

Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Trial in Beijing (Sintilimab, IBI310)

Recruiting
  • Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Dec 17, 2019

Advanced Solid Tumors Trial in Beijing (IBI310, Sintilimab)

Unknown status
  • Advanced Solid Tumors
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Oct 12, 2018